Abstract: A hypothermic oxygenated perfusion solution for repairing kidney injury and use thereof belongs to the technical field of medical treatment. The hypothermic oxygenated perfusion solution is an organ preservation solution carrying carbon monoxide-releasing molecules. The hypothermic oxygenated perfusion solution can significantly increase the perfusion flow of the kidney, reduce the intrarenal resistance and significantly improve the histopathological integrality. The hypothermic oxygenated perfusion solution is provided for specifically repairing the kidney from donation after circulatory death donors, and has a huge application prospect for clinical transformation.

Abstract: A micro puree machine has a mixing shaft attachable to a blade that is subject to both linear and rotational movement. A drive motor is contained within a lower portion of the machine housing and operatively couples to a first gear that engages a second gear on the mixing shaft for rotation of the mixing blade. A position motor within the upper housing operates to move the mixing blade linearly to engage the ingredients in the bowl. During both axial and rotational movement of the mixing shaft, the drive motor and the position motor remain stationary within their respective positions in the housing.

Abstract: An array substrate, a liquid crystal display panel and a display apparatus. The array substrate comprises: a substrate (10), a first insulating layer (20), a second insulating layer (30), a third insulating layer (40), a planarization layer (50), a first electrode layer (90A), a fourth insulating layer (70) and a second electrode layer (90B), the third insulating layer comprises a first interlayer insulating layer (40A), a second interlayer insulating layer (40B) and a third interlayer insulating layer (40C), which are sequentially stacked; the first interlayer insulating layer is located on the side of the second interlayer insulating layer close to the substrate (10), the third interlayer insulating layer is located on the side of the second interlayer insulating layer away from the substrate; the material of the first interlayer insulating layer and third interlayer insulating layer comprises silicon oxide, the material of the second interlayer insulating layer comprises silicon nitride.

Abstract: The present disclosure relates to a combined pharmaceutical composition containing a CDK4/6 inhibitor and a use thereof, and specifically relates to a combined pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and fulvestrant. The present disclosure further relates to a use of the combined pharmaceutical composition in treating breast cancer. The combined pharmaceutical composition of the present disclosure produces better therapeutic effects in reducing tumor growth or even eliminating tumors.

Abstract: Provided are compounds useful for treating of cancer and methods for treating of cancer, comprising administering to a subject in need thereof a compound described therein.

Abstract: A method and system for generating a variable rate irrigation (VRI) prescription map for a large sprinkler irrigation system is provided. The method includes: determining a minimum length of a VRI management zone along a truss direction of the sprinkler irrigation system; determining a minimum angle of the VRI management zone along a travel direction of the sprinkler irrigation system; dividing the VRI management zone to generate a VRI management zoning map; determining, according to a basic irrigation amount of VRI management and a spatial distribution map of crop water deficit or a spatial distribution map of soil water holding capacity (SWHC), an irrigation quota of each management sub-zone; and generating, according to a distribution map of irrigation quotas of all management sub-zones in combination with a travel speed of the sprinkler irrigation system and a duty cycle of a solenoid valve, the VRI prescription map.

Abstract: The MnZn ferrite material includes principal components and auxiliary components, where the principal components include: 52.5 mol % to 53.8 mol % of Fe2O3, 8.8 mol % to 12 mol % of ZnO, and the balance of MnO; the auxiliary components include: 0.35 wt % to 0.5 wt % of Co2O3, 0.03 wt % to 0.08 wt % of CaSiO3, 0.01 wt % to 0.04 wt % of Nb2O5, and 0.05 wt % to 0.12 wt % of TiO2 and RE elemental components; the RE elemental components include one or more from the group consisting of 0 wt % to 0.04 wt % of Gd2O3, 0 wt % to 0.02 wt % of Ho2O3, and 0 wt % to 0.03 wt % of Ce2O3; the auxiliary components are all represented by a mass percentage relative to a total mass of the Fe2O3, the MnO, and the ZnO.

Abstract: The disclosure is directed to an iron-nitride material having a polycrystalline microstructure including a plurality of elongated crystallographic grains with grain boundaries, the iron-nitride material including at least one of an ??-Fe16N2 phase and a body-center-tetragonal (bct) phase comprising Fe and N. The disclosure is also directed a method producing an iron-nitride material.

Abstract: A micro puree machine has a drive motor positioned within a lower portion of a housing extending along a vertical axis. A mixing shaft positioned within an upper portion of the housing extends at a non-parallel angle relative to the vertical axis. The bowl of ingredients is installed to an angled surface of the upper portion of the housing along the mixing shaft axis, allowing for easier viewing of the bowl installation.

Abstract: All example composition may include a plurality of grains including an iron nitride phase. The plurality of grains may have an average wain size between about 10 nm and about 200 nm. An example technique may include treating a composition including a plurality of grains including au iron-based phase to adjust an average grain size of the plurality of grains to between about 20 nm and about 100 ma. The example technique may include nitriding the plurality of grains to form or grow an iron nitride phase.

Abstract: The invention provides a Saccharomyces cerevisiae strain for producing a human milk lipid substitute. By integrating a heterologous lysophosphatidic acid acyltransferase into Saccharomyces cerevisiae and knocking out its own natural lysophosphatidic acid acyltransferase, the content of palmitic acid (C16:0) at Sn-2 position of triacylglycerol produced by Saccharomyces cerevisiae is increased, to synthesize a human milk lipid substitute. On this basis, a metabolic pathway related gene is knocked out, to further increase the content of human milk lipid substitute in the product. In the present invention, a human milk lipid substitute is de novo synthesized by Saccharomyces cerevisiae for the first time, in which the total fatty acid is 15% or more, and the relative content of C16:0 at Sn-2 position reaches about 60%.

Abstract: The present disclosure relates to pharmaceutical compositions and methods for treating a disease or condition associated with opening of Cx43 hemichannels in astrocytes or osteocytes, preferably for treating an inflammatory disease or condition or a neurodegenerative disease such as spinal cord injury.

Abstract: The present disclosure relates to novel crystalline forms of ozanimod and preparation method thereof. The provided crystalline forms of ozanimod comprise crystalline form CS9, crystalline form CS10 and crystalline form CS11, and can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, stability, hygroscopicity and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.

Abstract: The present invention relates to four crystal forms of crisaborole in free form and the preparation method thereof. The present invention also relates to the pharmaceutical composition containing the crystal forms and the use thereof.

Abstract: The present invention relates to four crystal forms of crisaborole in free form and the preparation method thereof. The present invention also relates to the pharmaceutical composition containing the crystal forms and the use thereof.

Abstract: The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.

Abstract: The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.

Abstract: Provided are an elastomeric-hose-compressing part, a cartridge, and a roller assembly for a pump head of a peristaltic pump, and a pump head for a peristaltic pump. The elastomeric-hose-compressing part includes a surface for compressing the elastomeric hose which has an arcuate shape along its length direction, wherein the surface for compressing the elastomeric hose is provided with flanges oppositely arranged on two side portions of the elastomeric-hose-compressing part in the width direction, the width direction of the elastomeric-hose-compressing part is perpendicular to the length direction, and the surface for compressing the elastomeric hose is formed by a continuous surface or by a plurality of surfaces sequentially arranged along the length direction.

Abstract: The present disclosure generally relates to compositions and methods for treating a disease or condition associated with opening of Cx43 hemichannels in astrocytes or osteocytes, preferably for treating an inflammatory disease or condition or a neurodegenerative disease such as spinal cord injury.